SonoCloud

Low Intensity Contact Ultrasound Implant 

Medical Applications

After the surgical resection of brain tumors, treatments using chemotherapy are typically administered. Unfortunately, most drug molecules barely penetrate into the brain tissue due to the blood-brain barrier (BBB).

The SonoCloud® medical device allows for a temporary disruption of the BBB and thus an increase in the intracerebral bioavailability of chemotherapeutic agents. It can in principle be used for the treatment of primary brain tumors (gliomas, glioblastomas, astrocytomas, …) as well as secondary brain tumors (metastases). The combined annual incidence in Europe and the USA is more than 250,000 patients for these indications.

A phase 1/2a clinical trial has been started to study the transient opening of the BBB with the SonoCloud® before administration of chemotherapy in patients with recurrent glioblastoma. In the long term, the SonoCloud® system can be used for other disorders for which the BBB limits the efficacy of drug therapies (neurodegenerative diseases such as Alzheimer’s).

The SonoCloud® Treatment

The SonoCloud® medical device is implanted in the skull, normally following a surgical resection of the tumor. If the patient cannot be operated on, the SonoCloud® can be implanted in a burr hole performed for a diagnostic biopsy or during a special surgical act under local anesthesia. After implantation, the skin is used to recover the implant. The implant is activated before each chemotherapy session using a transdermal needle that connects the implant to an external generator. The connection to the implant can be performed by a nurse. The ultrasound is emitted directly to the brain tissue, without having to pass the skull, to temporarily open the blood-brain barrier. Finally, even large molecules can be effectively delivered to the brain after disruption of the BBB.

chien BHE 

The figure shows the opening of the blood-brain barrier using the SonoCloud® in an animal model. Note the contrast enhancement in the T1w MR image, which shows the region of BBB disruption. After 6 hours, the BBB integrity is restored.

 

  • unnamed-2
    unnamed-3

     
  • News

    14.10.2016
    CarThera secures €5.7 million in funding for its DOME project

    October 12, 2016 – CarThera has received a grant of €5.7 million ($6.4m) for its DOME project. The funding was awarded under the call for proposals ‘Structuring R&D Projects for Competitiveness’ from France’s ‘Investments for the Future Program’, led by the General Investment Commission and run by Bpifrance.

    The grant will finance our SonoCloud Phase 2b/3 study in glioblastoma that will involve around 200 patients at centers in Europe and the United States. It will also fund a number of exploratory studies, including one on Alzheimer’s disease, building on the findings from the Phase 1/2a study that paved the way for a broader array of clinical indications.

    15.06.2016
    A world first published in Science Translational Medicine

    SonoCloud® uses ultrasound to achieve permeability of blood vessels in human brain, allowing increased penetration of therapeutic molecules

    Scientific paper published on June 15th 2016 in Science Translational Medicine supports concept of intracranial ultrasound implant developed by CarThera
     
    Research teams from AP-HP hospitals, UPMC University, INSERM laboratories and the ICM incubator performed this breakthrough on brain tumors, paving the way for broader applications in neurological disorders

    27.04.2016
    The Biovision 2016 Investor Conference selection committee special award went to CarThera!

    The Investor Conference of Biovision is a unique opportunity for selected startups (28 over 120 candidates) to pitch in front of a jury of 15 of the major European VC.

    Biovision, The World Life Sciences Forum, brings together international decision makers from the academic, private, policy-making and civil society sectors. It took place 13–14 April 2016 in Lyon, France.